Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.57 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.57 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.57 |
| ▸ | PSMA2 | P25787 | 4/20 | 0.57 |
| ▸ | PSMA3 | P25788 | 4/20 | 0.57 |
| ▸ | PSMA4 | P25789 | 4/20 | 0.57 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.57 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.57 |
| ▸ | PSMA5 | P28066 | 4/20 | 0.57 |
| ▸ | PSMB4 | P28070 | 4/20 | 0.57 |
| ▸ | PSMB6 | P28072 | 4/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.57 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.57 |
| ▸ | PSMB3 | P49720 | 4/20 | 0.57 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.57 |
| ▸ | PSMA6 | P60900 | 4/20 | 0.57 |
| ▸ | PSMA8 | Q8TAA3 | 4/20 | 0.57 |
| ▸ | PSMB7 | Q99436 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841270 | 0.85 | DDR1 (0.51) | CES2PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL2483079 | 0.84 | JAK2 (0.56) | EGLN1SORT1MCL1TDP1 | |
| SCHEMBL13753088 | 0.83 | CES2 (0.60) | CES2PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL5220850 | 0.81 | CES2 (0.66) | CES2PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL10888620 | 0.81 | EGLN1 (0.46) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL13753149 | 0.81 | POLB (0.59) | CES2PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL4007613 | 0.80 | GAA (0.62) | EGLN1POLB | |
| SCHEMBL10777286 | 0.79 | PPARG (0.46) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL3888117 | 0.78 | CCR2 (0.50) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL2481837 | 0.78 | PSMB11 (0.53) | CES2PSMB11PSMA7PSMB1PSMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| CN-102317278-A | The 4-azetidinyl of CCR2-1-heteroaryl-hexalin antagonist | JANSSEN PHARMACEUTICA NV | 2012-01-11 | — | — | CN | disclosed |
| EP-2376475-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica N.V. (BE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | CES2 846/4885PSMB11 3216/4885PSMA7 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.